Unresectable Stage III Non-Small Cell Lung Cancer

• IV (Adults ≥30 kg): 10 mg/kg every 2 wk or 1500 mg every 4 wk; continue until disease progression, unacceptable toxicity, or a maximum of 12 mo.
• IV (Adults <30 kg): 10 mg/kg every 2 wk until disease progression, unacceptable toxicity, or a maximum of 12 mo.

Metastatic Non-Small Cell Lung Cancer

• IV (Adults ≥30 kg): Nonsquamous: Cycles 1–4: 1500 mg on Day 1 every 3 wk (administered prior to platinum-based chemotherapy and following tremelimumab); Cycle 5 (3 wk after previous durvalumab dose): 1500 mg on Day 1 (administered prior to pemetrexed [if being used for maintenance]); Cycle 6 (4 wk after previous durvalumab dose): 1500 mg on Day 1 (administered prior to pemetrexed [if being used for maintenance] and following tremelimumab); Cycle 7 (4 wk after previous durvalumab dose) and beyond: 1500 mg on Day 1 every 4 wk (administered prior to pemetrexed [if being used for maintenance]); continue until disease progression or unacceptable toxicity. Squamous: Cycles 1–4: 1500 mg on Day 1 every 3 wk (administered prior to platinum-based chemotherapy and following tremelimumab); Cycle 5 (3 wk after previous durvalumab dose): 1500 mg on Day 1 (as monotherapy); Cycle 6 (4 wk after previous durvalumab dose): 1500 mg on Day 1 (administered following tremelimumab); Cycle 7 (4 wk after previous durvalumab dose) and beyond: 1500 mg on Day 1 every 4 wk (as monotherapy); continue until disease progression or unacceptable toxicity.
• IV (Adults <30 kg): Nonsquamous: Cycles 1–4: 20 mg/kg on Day 1 every 3 wk (administered prior to platinum-based chemotherapy and following tremelimumab); Cycle 5 (3 wk after previous durvalumab dose): 20 mg/kg on Day 1 (administered prior to pemetrexed [if being used for maintenance]); Cycle 6 (4 wk after previous durvalumab dose): 20 mg/kg on Day 1 (administered prior to pemetrexed [if being used for maintenance] and following tremelimumab); Cycle 7 (4 wk after previous durvalumab dose) and beyond: 20 mg/kg on Day 1 every 4 wk (administered prior to pemetrexed [if being used for maintenance]); continue until disease progression or unacceptable toxicity. Squamous: Cycles 1–4: 20 mg/kg on Day 1 every 3 wk (administered prior to platinum-based chemotherapy and following tremelimumab); Cycle 5 (3 wk after previous durvalumab dose): 20 mg/kg on Day 1 (as monotherapy); Cycle 6 (4 wk after previous durvalumab dose): 20 mg/kg on Day 1 (administered following tremelimumab); Cycle 7 (4 wk after previous durvalumab dose) and beyond: 20 mg/kg on Day 1 every 4 wk (as monotherapy); continue until disease progression or unacceptable toxicity.

Small Cell Lung Cancer

• IV (Adults ≥30 kg): 1500 mg every 3 wk for 4 cycles (administered prior to etoposide and either carboplatin or cisplatin on the same day), then 1500 mg every 4 wk (as monotherapy); continue until disease progression or unacceptable toxicity.
• IV (Adults <30 kg): 20 mg/kg every 3 wk for 4 cycles (administered prior to etoposide and either carboplatin or cisplatin on the same day), then 20 mg/kg every 4 wk (as monotherapy); continue until disease progression or unacceptable toxicity.

Biliary Tract Cancer

• IV (Adults ≥30 kg): 1500 mg every 3 wk for up to 8 cycles (administered prior to gemcitabine and cisplatin on the same day), then 1500 mg every 4 wk (as monotherapy); continue until disease progression or unacceptable toxicity.
• IV (Adults <30 kg): 20 mg/kg every 3 wk for up to 8 cycles (administered prior to gemcitabine and cisplatin on the same day), then 20 mg/kg every 4 wk (as monotherapy); continue until disease progression or unacceptable toxicity.

Hepatocellular Carcinoma

• IV (Adults ≥30 kg): 1500 mg administered following a single dose of tremelimumab on Day 1 of Cycle 1, then 1500 mg every 4 wk (as monotherapy); continue until disease progression or unacceptable toxicity.
• IV (Adults <30 kg): 20 mg/kg administered following a single dose of tremelimumab on Day 1 of Cycle 1, then 20 mg/kg every 4 wk (as monotherapy); continue until disease progression or unacceptable toxicity.